medcelerator · clinician one-pager

First FDA-Approved Pill for Children 4–11 With APDS

Joenja (leniolisib) — first labelled oral treatment for children 4–11 with APDS who weigh at least 27 kg

FDA Approved · United States · September 18, 2026

Condition: Activated PI3K Delta Syndrome

Who this is for

This is for caregivers of children 4–11 years with genetically confirmed APDS who weigh at least 27 kg (about 60 lb) and who may be candidates for labelled US Joenja as a twice-daily oral PI3Kδ inhibitor. It explains the September 2026 FDA expansion, weight-based 40/50/70 mg dosing, APDS Assist navigation, and how to talk with an immunology / genetics clinician — without treating this as approved under 4 years or under 27 kg, a DIY import, or “approved” as funded. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217759s006lbl.pdf

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/joenja-leniolisib-pediatric